16:57 , Mar 22, 2019 |  BC Week In Review  |  Financial News

Spinal cord injury company NervGen raises $10M IPO

NervGen Pharma raised $10 million in an IPO on TSX Ventures on March 13. It plans to submit an IND late this year for lead candidate, NVG-291, to treat spinal cord injury and peripheral nerve...
19:21 , Oct 11, 2018 |  BC Innovations  |  Distillery Therapeutics

Autoimmune disease

INDICATION: Multiple sclerosis (MS) Mouse studies suggest PTPRS mimetics could help treat MS. In the experimental autoimmune encephalomyelitis (EAE) mouse model of MS, a small peptide mimetic of PTPRS decreased clinical disease scores, demyelinated spinal...
07:00 , May 28, 2015 |  BC Innovations  |  Distillery Therapeutics

Therapeutics: Protein tyrosine phosphatase receptor type S (PTPRS)

Autoimmune disease INDICATION: Rheumatoid arthritis (RA) Mouse and patient sample studies suggest a PTPRS decoy could help treat RA. In RA patients and mouse models of the disease, PTPRS is highly expressed in fibroblast-like synoviocytes...
07:00 , May 28, 2015 |  BC Innovations  |  Targets & Mechanisms

Joint attack

A newly discovered pathway that causes joint erosion in rheumatoid arthritis could lead to a new class of therapies that act locally in cells of the synovial lining and avoid the drawbacks of immunosuppressants. The...
08:00 , Feb 19, 2015 |  BC Innovations  |  Distillery Therapeutics

Therapeutics: Protein tyrosine phosphatase receptor type S (PTPRS)

Neurology INDICATION: Spinal cord injury (SCI) In vitro and mouse studies suggest inhibiting PTPRS could help promote recovery after SCI. In an in vitro model of the recovery-inhibiting extracellular matrix (ECM) that forms post-SCI, adult...
08:00 , Nov 5, 2009 |  BC Innovations  |  Cover Story

Unblocking axonal regeneration

For nearly 20 years it has been known that growth-inhibitory molecules called chondroitin sulfate proteoglycans , or CSPGs, are a major impediment to axonal regeneration at sites of CNS injury. However, blocking CSPG signaling to...
07:00 , Oct 29, 2009 |  BC Innovations  |  Distillery Therapeutics

Indication: Neurology

Indication Target/marker/ pathway Summary Licensing status Publication and contact information Neurology Spinal cord injury (SCI) Protein tyrosine phosphatase receptor type S (PTPRS; PTPd) In vitro and mouse studies suggest that inhibiting PTPRS could help treat...